PaxMedica Inc (PXMD)

PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101

TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (the “Company” or...

PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy

TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a...

PaxMedica's CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast

LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization...

PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101

TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the...

PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness

Emergent shortages of the drug used to treat the most severe form of African sleeping sickness creates...

PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission

TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a...

PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments

TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a...

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 4 - Statement of changes in beneficial ownership of securities

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]